VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the test's potential to improve patient outcomes.
Multiple studies have shown that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Most of this research has been peer-reviewed and published, with experts noting consistency across different countries and patient populations. According to the company, the low-cost nucleosome quantification technology could help personalize care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies.
For more details, the full press release is available at https://ibn.fm/2IH3m. VolitionRx is a multinational company focused on advancing epigenetics, developing easy-to-use blood tests for early detection and monitoring of diseases such as cancers and sepsis. The company's research and development activities are centered in Belgium, with offices in the U.S. and London. For further information, visit https://volition.com/.
This announcement is important because sepsis remains a leading cause of death worldwide, and early, accurate diagnosis is critical. The growing evidence for Nu.Q NETs could lead to improved diagnostic and monitoring tools, potentially reducing mortality and healthcare costs. The consistency of findings across studies strengthens the case for clinical adoption, and the test's low cost makes it accessible in various healthcare settings. As VolitionRx continues to gather data, the Nu.Q assay may become a standard tool in sepsis management, helping clinicians tailor treatments to individual patients and improve outcomes.
